Evidence map›Paper›PMID 39294659›Full record

ArticleItalian journal of pediatrics2024

The assessment of pentraxin 3: a diagnostic and prognostic biomarker in lower respiratory tract infections in children.

Shaimaa Madkour, Mona Gamal Mostafa, Huda El-Kady

Abstract read
In one paragraph

Article in Italian journal of pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Unveiling a novelFrontiers in medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shaimaa MadkourDepartment of Pediatrics, Faculty of Medicine, Fayoum University, Fayoum, Egypt. sma23@fayoum.edu.eg.ORCID http://orcid.org/0009-0003-8737-256X
Mona Gamal MostafaDepartment of clinical and chemical pathology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Huda El-KadyDepartment of Pediatrics, Faculty of Medicine, Fayoum University, Fayoum, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPentraxin 3 (PTX3) is an acute-phase reactant that is elevated in the plasma during inflammatory responses. We aimed to evaluate the utility of PTX3 as a clinical marker in children with lower respiratory tract infections (LRTIs) and the association between PTX3 and LRTIs severity.

methodsWe included 60 patients admitted to Fayoum University Hospital with LRTIs fulfilling the WHO criteria for diagnosing LRTIs. We collected data on peak temperature, respiratory rate, heart rate, oxygen saturation upon admission, and length of hospital stay. The complete blood count (CBC), C-reactive protein (CRP) level, and PTX3 were measured upon admission.

resultsPTX3 levels were significantly correlated with peak temperature, duration of hospital stay, the Pediatric Respiratory Severity Score (PRESS), total leucocytic count (TLC), CRP, and blood cultures.

conclusionPTX-3 represented the severity of the disease and predicted the prognosis. Pentraxin levels demonstrate a statistically significant sensitivity of (93.3%) and a specificity of (70%) at the cut-off value (of 8.84) with an area under the curve (90.7%) in the diagnosis of LRTIs.

Indexed as

BiomarkersC-Reactive ProteinRespiratory Tract InfectionsSerum Amyloid P-ComponentSeverity of Illness IndexChildChild, PreschoolFemaleHumansInfantMalePentraxinsPrognosisSensitivity and SpecificityBiomarkersC-Reactive ProteinPentraxinsSerum Amyloid P-ComponentChildrenC-reactive proteinLower respiratory infectionsPentraxin 3

Identifiers

PMID39294659
PMCPMC11411843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.